Read Latest Abstract Based on Fairbanks Research

The abstract for the paper that Fairbanks CEO Dr. Alan Schneyer would have been discussing at the canceled ENDO 2020 meeting in March has now been published in Journal of the Endocrine Society. The abstract is titled “FSTL3 Neutralizing Antibodies Restore Function to Diabetic Mouse and Human Islets: A New Approach for Treating Diabetes”.

The studies that would have been presented include a determination of how the therapy works on its target FSTL3 as well as a demonstration that the therapy can restore insulin secretion to diabetic beta cells.  Animal studies are underway that hopefully will lead to human trials in the not too distant future.